GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » 1-Year ROIIC %

GNMLF (Genomma Lab InternacionalB de CV) 1-Year ROIIC % : -29.76% (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV 1-Year ROIIC %?

1-Year Return on Invested Incremental Capital (1-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 1-year. Genomma Lab InternacionalB de CV's 1-Year ROIIC % for the quarter that ended in Sep. 2024 was -29.76%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Genomma Lab InternacionalB de CV's 1-Year ROIIC % or its related term are showing as below:

GNMLF's 1-Year ROIIC % is ranked worse than
71.05% of 1012 companies
in the Drug Manufacturers industry
Industry Median: 1.765 vs GNMLF: -29.76

Genomma Lab InternacionalB de CV 1-Year ROIIC % Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's 1-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV 1-Year ROIIC % Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
1-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.09 52.40 -12.72 -104.80 75.68

Genomma Lab InternacionalB de CV Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
1-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -115.90 75.68 123.54 -90.94 -29.76

Competitive Comparison of Genomma Lab InternacionalB de CV's 1-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's 1-Year ROIIC %, along with its competitors' market caps and 1-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's 1-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's 1-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's 1-Year ROIIC % falls into.



Genomma Lab InternacionalB de CV 1-Year ROIIC % Calculation

Genomma Lab InternacionalB de CV's 1-Year ROIIC % for the quarter that ended in Sep. 2024 is calculated as:

1-Year ROIIC %=1-Year Incremental Net Operating Profit After Taxes (NOPAT)**/1-Year Incremental Invested Capital
=( 94.4427 (Sep. 2024) - 124.8709 (Sep. 2023) )/( 995.487 (Sep. 2024) - 1033.084 (Sep. 2023) )
=-30.4282/-37.597
=80.93%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of NOPAT and Invested Capital was used to calculate 1-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) 1-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Genomma Lab InternacionalB de CV 1-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's 1-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.